VOLUNTARY ANNOUNCEMENT - Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.HUTCHMED (China) Limited 和黄医药（中国）有限公司 (?ncorporated in the Cayman ?slands with limited liability) (Stock Code: ??) VOLUNTARY ANNOUNCEMENT Save the Date: HUTCHMED to Present R&D Updates on July 9 2024 — HUTCHMED will host in-person presentation and online webinar on Tuesday July 9 — HUTCHMED (China) Limited (“HUTCHMED”) today announces that it will host a R&D update in Shanghai China and via webcast on Tuesday July 9 2024.During the event the senior management team will share insights into the Company’s R&D strategy and vision. Additionally the team will provide updates on certain programs within HUTCHMED’s extensive and innovative pipeline. This will include updates on the Phase ??? ESL?M-01 and Phase ??/??? ESL?M-02 studies of our Syk inhibitor sovleplenib in immune thrombocytopenia (“?TP”) and warm antibody autoimmune hemolytic anemia (“wA?HA”) respectively; the surufatinib Phase ??/??? study for metastatic pancreatic ductal adenocarcinoma (“PDAC”); and the Phase ??? RAPHAEL study of our ?DH1/2 inhibitor HMPL-306 in acute myeloid leukemia (“AML”).The in-person event will take place from 3:00 p.m. to 5:00 p.m. HKT in Chinese (Putonghua) in Shanghai. A live webcast will be held simultaneously. Attendance for the in-person event is by invitation only.An English language webcast will take place from 8:30 p.m. HKT / 8:30 a.m. EDT / 1:30 p.m. BST on Tuesday July 9 for approximately two hours.Both webcasts will be live and can be accessed via www.hutch-med.com/event. ?nvestors interested in listening to a webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.About HUTCHMED HUTCHMED (Nasdaq/A?M:HCM; HKEX:13) is an innovative commercial-stage biopharmaceutical company. ?t is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. ?t has approximately 5000 personnel across all its companies at the center of which is a team of about 1800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world with its first three oncology drugs marketed in China the first of which is also marketed in the U.S. For more information please visit: www.hutch-med.com or follow us on Linked?n. 1Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. For further discussion of these and other risks see HUTCHMED’s filings with the U.S.Securities and Exchange Commission The Stock Exchange of Hong Kong Limited and on A?M. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information future events or circumstances or otherwise.By Order of the Board Edith Shih Non-executive Director and Company Secretary Hong Kong June 24 2024 As at the date of this announcement the Directors of the Company are: Chairman and Non-executive Director: Non-executive Directors: Dr Dan ELDAR Ms Edith SH?H Ms Ling YANG Executive Directors: Dr Weiguo SU Independent Non-executive Directors: (Chief Executive Officer and Mr Paul Rutherford CARTER Chief Scientific Officer) (Senior ?ndependent Director) Mr CHENG Chig Fung Johnny Dr Renu BHAT?A (Chief Financial Officer) Mr Graeme Allan JACK Professor MOK Shu Kam Tony 2